These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23981925)

  • 1. Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases.
    Spinelli FR; Valesini G
    Clin Exp Rheumatol; 2013; 31(6):954-63. PubMed ID: 23981925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.
    Matucci A; Cammelli D; Cantini F; Goletti D; Marino V; Milano GM; Scarpa R; Tocci G; Maggi E; Vultaggio A
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):3-10. PubMed ID: 27924646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine history knowledge of subcutaneous anti-TNF receiving rheumatology patients.
    Nolan TJ; O'Connor MB; Bond U; Swan J; Phelan MJ
    Rheumatol Int; 2013 Jul; 33(7):1907-8. PubMed ID: 22441967
    [No Abstract]   [Full Text] [Related]  

  • 4. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.
    Vincent FB; Morand EF; Murphy K; Mackay F; Mariette X; Marcelli C
    Ann Rheum Dis; 2013 Feb; 72(2):165-78. PubMed ID: 23178294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of TNF alpha inhibitors in rheumatology: many questions, enough answers?
    Wendling D; Verhoeven F; Guillot X; Prati C
    Expert Opin Drug Saf; 2017 Jan; 16(1):1-3. PubMed ID: 27737601
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.
    Ha C; Mathur J; Kornbluth A
    Expert Rev Gastroenterol Hepatol; 2015 Apr; 9(4):497-505. PubMed ID: 25600263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
    Haraoui B
    J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction.
    Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):1. PubMed ID: 27924647
    [No Abstract]   [Full Text] [Related]  

  • 12. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cytokine antibodies for rheumatic diseases.
    Atzeni F; Sarzi-Puttini P
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious infections associated with anticytokine therapies in the rheumatic diseases.
    Giles JT; Bathon JM
    J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor therapies in immune-mediated rheumatic diseases. Other observations from the clinic.
    Russell AS; Rosenbaum JT
    J Rheumatol Suppl; 2010 May; 85():53-62. PubMed ID: 20436165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 18. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
    Giardina AR; Ferraro D; Ciccia F; Ferrante A; Di Stefano R; Craxì A; Triolo G
    Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
    Aikawa NE; Twardowsky Ade O; Carvalho JF; Silva CA; Silva IL; Ribeiro AC; Saad CG; Moraes JC; Toledo RA; Bonfá E
    Clinics (Sao Paulo); 2011; 66(7):1171-5. PubMed ID: 21876969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist.
    Pincus T; Braun J; Kavanaugh A; Smolen JS
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S1-3. PubMed ID: 24129127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.